EyePoint Pharmaceuticals Inc (EYPT)
8.95
+0.60
(+7.19%)
USD |
NASDAQ |
Nov 22, 16:00
8.935
-0.02
(-0.17%)
After-Hours: 20:00
EyePoint Pharmaceuticals Cash from Financing (Quarterly): 11.89M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 11.89M |
| June 30, 2024 | 0.329M |
| March 31, 2024 | 0.115M |
| December 31, 2023 | 218.48M |
| September 30, 2023 | 10.36M |
| June 30, 2023 | -36.66M |
| March 31, 2023 | -5.119M |
| December 31, 2022 | -0.058M |
| September 30, 2022 | 0.092M |
| June 30, 2022 | -0.276M |
| March 31, 2022 | -0.448M |
| December 31, 2021 | 108.52M |
| September 30, 2021 | -0.002M |
| June 30, 2021 | -0.381M |
| March 31, 2021 | 108.77M |
| December 31, 2020 | 10.48M |
| September 30, 2020 | 4.904M |
| June 30, 2020 | 1.662M |
| March 31, 2020 | 20.45M |
| December 31, 2019 | 1.945M |
| September 30, 2019 | 2.371M |
| June 30, 2019 | 17.91M |
| March 31, 2019 | 11.63M |
| September 30, 2018 | 28.86M |
| June 30, 2018 | 30.27M |
| Date | Value |
|---|---|
| March 31, 2018 | 23.36M |
| December 31, 2017 | 6.081M |
| September 30, 2017 | 0.963M |
| June 30, 2017 | 6.099M |
| March 31, 2017 | 2.395M |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.009M |
| June 30, 2016 | 0.122M |
| March 31, 2016 | 16.53M |
| December 31, 2015 | 0.329M |
| September 30, 2015 | 0.009M |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.179M |
| September 30, 2014 | 0.056M |
| June 30, 2014 | -0.014M |
| March 31, 2014 | 7.457M |
| December 31, 2013 | 1.62M |
| September 30, 2013 | 9.981M |
| June 30, 2013 | 0.00 |
| March 31, 2013 | 0.00 |
| December 31, 2012 | -0.066M |
| September 30, 2012 | 4.735M |
| June 30, 2012 | 0.00 |
| March 31, 2012 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-36.66M
Minimum
Jun 2023
218.48M
Maximum
Dec 2023
22.75M
Average
0.9955M
Median
Cash from Financing (Quarterly) Benchmarks
| Cassava Sciences Inc | 0.00 |
| Regeneron Pharmaceuticals Inc | -634.00M |
| Adverum Biotechnologies Inc | 0.00 |
| Regenxbio Inc | -10.86M |
| Editas Medicine Inc | 0.00 |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -39.03M |
| Cash from Investing (Quarterly) | 16.20M |
| Free Cash Flow | -118.04M |
| Free Cash Flow Per Share (Quarterly) | -0.7457 |
| Free Cash Flow to Equity (Quarterly) | -40.60M |
| Free Cash Flow Yield | -26.02% |